Hansa Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	701.08	405.28	732.06	1,496	651.34
Short-Term Investments	-	-	-	-	237.62
Cash & Short-Term Investments	701.08	405.28	732.06	1,496	888.96
Cash Growth	72.99%	-44.64%	-51.07%	68.31%	-35.47%
Accounts Receivable	53.87	26.78	78.03	42.96	9.71
Other Receivables	18.21	17.49	15.73	24.22	13.53
Receivables	72.08	44.27	93.76	67.18	23.24
Inventory	6.13	2.61	1.51	0.97	0.24
Prepaid Expenses	3.47	2.84	3.06	3.52	3.34
Other Current Assets	13.85	12.24	24.76	36.85	26.56
Total Current Assets	796.61	467.24	855.15	1,605	942.34
Property, Plant & Equipment	13.35	17.88	27.07	35.84	41.71
Other Intangible Assets	17.41	20.46	23.17	26.01	28.76
Long-Term Accounts Receivable	126.25	118.19	-	-	-
Long-Term Deferred Charges	213.15	176.88	112.65	20.85	-
Total Assets	1,167	800.64	1,018	1,687	1,013
Accounts Payable	54.06	37.62	86.97	62.48	53.36
Accrued Expenses	94.23	97.89	116.54	100.32	78.22
Current Portion of Long-Term Debt	136.87	-	-	-	-
Current Portion of Leases	8.28	7.68	7.5	7.17	6.89
Current Income Taxes Payable	1.83	2.71	1.6	0.6	-
Current Unearned Revenue	-	16.33	41.47	40.43	24.96
Other Current Liabilities	115.4	93.45	66.91	53.71	7.79
Total Current Liabilities	410.66	255.69	320.99	264.71	171.22
Long-Term Debt	790.53	1,065	844.9	762.6	-
Long-Term Leases	3	6.68	14.36	21.33	28.49
Long-Term Unearned Revenue	1.61	-	-	29.5	47.02
Long-Term Deferred Tax Liabilities	0.26	0.17	0.37	0.41	0.43
Other Long-Term Liabilities	49.71	63.3	5.3	5.95	8.08
Total Liabilities	1,256	1,390	1,186	1,084	255.24
Common Stock	101.76	67.81	55.03	55.03	46.34
Additional Paid-In Capital	4,457	3,454	3,083	3,022	2,573
Retained Earnings	-4,644	-4,110	-3,303	-2,471	-1,860
Treasury Stock	-2.03	-2.36	-2.36	-2.59	-1.86
Comprehensive Income & Other	-2.03	0.94	-0.41	0.01	0.13
Shareholders' Equity	-88.99	-589.83	-167.88	602.91	757.57
Total Liabilities & Equity	1,167	800.64	1,018	1,687	1,013
Total Debt	938.67	1,079	866.77	791.09	35.38
Net Cash (Debt)	-237.59	-673.73	-134.71	705.09	853.58
Net Cash Growth	-	-	-	-17.40%	-37.81%
Net Cash Per Share	-2.93	-10.72	-2.56	15.70	19.19
Filing Date Shares Outstanding	101.76	67.81	52.67	52.44	44.47
Total Common Shares Outstanding	101.76	67.81	52.67	52.44	44.47
Working Capital	385.95	211.56	534.16	1,340	771.12
Book Value Per Share	-0.87	-8.70	-3.19	11.50	17.03
Tangible Book Value	-106.4	-610.29	-191.05	576.9	728.81
Tangible Book Value Per Share	-1.05	-9.00	-3.63	11.00	16.39

Source: S&P Global Market Intelligence. Standard template. Financial Sources.